30 closest matches · ranked by relevance
HIV Infections · Lipodystrophy
Primary: Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12 — 0.5; -32.6 Square Centimeter (cm^2) — p=<0.001
HIV-1
Primary: Change From Baseline in Limb Fat at Week 48 — 392; -257 grams (g) — p=0.0014
HIV-Associated Lipodystrophy Syndrome
Primary: Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48 — 0.02; -0.02; 0.02; -0.01 ratio — p=0.48
HIV Infections
Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
HIV Infection
Primary: Total Limb Fat Mass — 8.84; 9.13 kg
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
HIV Lipodystrophy
Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale
Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Primary: Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan — -1.7 kg — p=<0.001
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
HIV Lipodystrophy
Primary: Rate of Total Lipolysis — 0.649; 0.767 mmol FFA/kg/h
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Change in Fat mtDNA Content — -169; 321 copies/cell
HIV Infections · Lipoatrophy
Primary: Change in Limb Fat (g) From Baseline — 74; 110 grams — p=0.64
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell
HIV
Primary: Insulin Stimulated Glucose Uptake — 7.70; 8.58 mg/min per μIU/ml — p=0.71
HAART-induced Lipodystrophy and Metabolic Syndrome
Primary: Serum Lipid Levels — 228.8; 219.7; 113.0; 105.7 mg/dl
HIV-Associated Lipodystrophy Syndrome · Insulin Resistance · HIV Infections
Primary: Change in Insulin Sensitivity — 0.20; 1.44; -0.63; 0.14 uU*10^-4*min*ml^-1
HIV Infections · Lipodystrophy
Primary: Fasting Serum Triglycerides — 237; 341 mg/dL — p=0.84
HIV Infections · Type 2 Diabetes · Obesity
Primary: Insulin-stimulated Glucose Disposal Rate — 30; 34; 37; 48 µmol glucose/kg FFM/min
Lipodystrophy · HIV Infections
Primary: Changes From Baseline in Fasting Blood Glucose at Week 52 — 0; -2; 1 mg/dL — p=>0.05
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
HIV Infection
Primary: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT) — 8.2; 10.7; 12.9 micron/year — p=0.013
HIV Infections
Primary: Change in Limb Fat at 48 Weeks — 448; 153 grams — p=0.02
HIV Posterior Cheek Enlargement
Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume
HIV Infections · Lipodystrophy
Primary: Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2) — -6.6; 1.8 cm^2 — p=0.52
HIV · Metabolic Syndrome · Osteopenia
Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
HIV Infections · Metabolic Syndrome X
Primary: Carotid Intima Media Thickness — -0.02; -0.02; 0.00; 0.03 mm — p=0.37
HIV · HIV Lipodystrophy
Primary: Liver Fat — -2.0; 0.9 Change in hepatic lipid-to-water %